# Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen

> **NCT00984399** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 31 (actual)

## Conditions studied

- Atrophic Vaginitis
- Breast Cancer

## Interventions

- **DRUG:** Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist

## Key facts

- **NCT ID:** NCT00984399
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-22
- **Primary completion:** 2024-05-13
- **Final completion:** 2024-05-13
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00984399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00984399, "Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00984399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*